Opus Genetics Inc. (IRD)
IRD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/0001140361-26-009247-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | IRD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001228627 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $14.2M |
| Net income | -$49.6M |
| Operating income | -$38.6M |
| Net margin | -349.3% |
| Operating margin | -271.9% |
| Revenue growth | +29.1% |
| Cash | $45.1M |
| Total assets | $50.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 27.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $89.0M cash; operating cash flow -$12.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 96,654,336 (2026-11-06); 68,964,208 a year earlier; 22,637,600 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 3 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-08-07 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Detroit, Michigan, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $324K, sold $16.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.1M | -$46.5M | -$14.0M | $89.0M | $35.7M | $7.9M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $755K | -$8.1M | -$11.9M | $88.8M | $35.3M | $9.9M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $2.2M | -$65.5M | -$12.7M | $60.0M | $1.2M | $12.0M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $3.9M | -$16.5M | -$9.8M | $45.1M | $1.1M | $14.2M | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | $3.1M | -$17.5M | -$6.2M | $30.8M | $1.1M | $14.6M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $2.9M | -$7.4M | -$10.3M | $32.4M | $1.0M | $15.4M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $4.4M | -$8.2M | -$9.0M | $41.8M | No debt tags | $13.7M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $4.3M | -$35.1M | -$7.4M | $30.3M | $0 | $11.0M | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-08-07 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEF 14A | 2026-03-23 |
Source: SEC EDGAR submissions feed, 1,005 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.8% |
| 1 month | -6.1% |
| 3 months | +7.0% |
| Year to date | +98.0% |
| 1 year | +115.1% |
| From 52-week high | -34.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PEPG | PepGen Inc. | $4.19 | -3.90% | $395.0M |
| RLMD | Relmada Therapeutics Inc. | $3.61 | -14.25% | $385.2M |
| CRMD | CorMedix Inc. | $4.82 | +3.43% | $383.4M |
| CTNM | Contineum Therapeutics Inc. | $9.67 | -1.93% | $379.7M |
| PBYI | Puma Biotechnology Inc | $7.34 | -5.53% | $379.5M |
| PRTA | Prothena Corporation plc | $7.97 | -2.33% | $409.3M |
| SPRY | ARS Pharmaceuticals Inc. | $3.59 | -7.71% | $360.9M |
| AVTX | Avalo Therapeutics Inc. | $7.37 | -5.03% | $426.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier